GCG and Stroke: More recently, for example, a glucagon-like peptide-1 (GLP-1) analogue, Semaglutide, demonstrated cardiovascular protective benefits, showing reduced relative and absolute risk of Major Adverse Cardiac Events (MACE) (defined as CV death, non-fatal stroke, non-fatal MI) when compared to placebo (Husain et al., 2020).